Final Dose Level Initiated in Ph 1 Trial of THE001
“After observing early signs of efficacy in our ongoing trial, this is another important milestone for our company, as it proves that THE001 can be administered safely,“ said Dr. Frank Hermann, CMO of Thermosome. “Of note, there were no signs of renal or cardiac impairment and no dedicated formulation-related adverse events such as infusion-related reactions due to the innovative liposomal formulation. No trial participant had to discontinue treatment due to adverse events. Together with the previously reported pharmacokinetic and anti-tumor activity data, the overall data from the trial look very encouraging as of now. They underline the great potential of THE001 plus regional hyperthermia in STS as a tolerable, innovative treatment modality that has significantly improved local clinical activity with non-inferior systemic exposure to doxorubicin, but with a favorable pharmacokinetic profile.“
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000